Jenya Antonova
Independent Health Economist with deep expertise in PRO and COA, fusing a passion for winning strategies with a track record of award-winning research excellence
Research Interests
About
Publications
Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication Ratio
Journal of Managed Care & Specialty Pharmacy / Nov 01, 2017
Luskin, A. T., Antonova, E. N., Broder, M. S., Chang, E., Raimundo, K., & Solari, P. G. (2017). Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication Ratio. Journal of Managed Care & Specialty Pharmacy, 23(11), 1117–1124. https://doi.org/10.18553/jmcp.2017.23.11.1117
Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO
Annals of Allergy, Asthma & Immunology / Dec 01, 2017
Chipps, B. E., Zeiger, R. S., Luskin, A. T., Busse, W. W., Trzaskoma, B. L., Antonova, E. N., Pazwash, H., Limb, S. L., Solari, P. G., Griffin, N. M., & Casale, T. B. (2017). Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. Annals of Allergy, Asthma & Immunology, 119(6), 524-532.e2. https://doi.org/10.1016/j.anai.2017.09.056
Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study
Journal of the American Academy of Dermatology / Apr 01, 2018
Casale, T. B., Win, P. H., Bernstein, J. A., Rosén, K., Holden, M., Iqbal, A., Trzaskoma, B. L., Yang, M., Antonova, E. N., Murphy, T., Scarupa, M. D., Sofen, H., & Kaplan, A. (2018). Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study. Journal of the American Academy of Dermatology, 78(4), 793–795. https://doi.org/10.1016/j.jaad.2017.10.010
Importance of angioedema-free days in patients with chronic idiopathic or spontaneous urticaria
Annals of Allergy, Asthma & Immunology / Apr 01, 2017
Zazzali, J. L., Kaplan, A., Maurer, M., Raimundo, K., Trzaskoma, B., Antonova, E. N., & Rosén, K. E. (2017). Importance of angioedema-free days in patients with chronic idiopathic or spontaneous urticaria. Annals of Allergy, Asthma & Immunology, 118(4), 524. https://doi.org/10.1016/j.anai.2016.12.023
Corticosteroid-related toxicity in patients with chronic idiopathic urticaria‐chronic spontaneous urticaria
Allergy and Asthma Proceedings / Nov 01, 2016
Ledford, D., Broder, M. S., Antonova, E., Omachi, T. A., Chang, E., & Luskin, A. (2016). Corticosteroid-related toxicity in patients with chronic idiopathic urticaria‐chronic spontaneous urticaria. Allergy and Asthma Proceedings, 37(6), 458–465. https://doi.org/10.2500/aap.2016.37.3999
Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis
ClinicoEconomics and Outcomes Research / Oct 01, 2016
Luskin, A., Antonova, E., Broder, M., Chang, E., Omachi, T., & Ledford, D. (2016). Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis. ClinicoEconomics and Outcomes Research, Volume 8, 641–648. https://doi.org/10.2147/ceor.s115025
Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies
Clinical and Translational Allergy / Aug 18, 2016
Gimenéz-Arnau, A. M., Spector, S., Antonova, E., Trzaskoma, B., Rosén, K., Omachi, T. A., Stull, D., Balp, M.-M., & Murphy, T. (2016). Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies. Clinical and Translational Allergy, 6(1). https://doi.org/10.1186/s13601-016-0120-0
Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies
Annals of Allergy, Asthma & Immunology / Oct 01, 2016
Zazzali, J. L., Kaplan, A., Maurer, M., Raimundo, K., Trzaskoma, B., Solari, P. G., Antonova, E., Mendelson, M., & Rosén, K. E. (2016). Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies. Annals of Allergy, Asthma & Immunology, 117(4), 370-377.e1. https://doi.org/10.1016/j.anai.2016.06.024
Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria
Journal of Allergy and Clinical Immunology / Feb 01, 2016
Kaplan, A., Ferrer, M., Bernstein, J. A., Antonova, E., Trzaskoma, B., Raimundo, K., Rosén, K., Omachi, T. A., Khalil, S., & Zazzali, J. L. (2016). Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. Journal of Allergy and Clinical Immunology, 137(2), 474–481. https://doi.org/10.1016/j.jaci.2015.08.023
Resource Use and Costs in an Insured Population of Patients with Chronic Idiopathic/Spontaneous Urticaria
American Journal of Clinical Dermatology / Jun 09, 2015
Broder, M. S., Raimundo, K., Antonova, E., & Chang, E. (2015). Resource Use and Costs in an Insured Population of Patients with Chronic Idiopathic/Spontaneous Urticaria. American Journal of Clinical Dermatology, 16(4), 313–321. https://doi.org/10.1007/s40257-015-0134-8
Can Bundled Payment Improve Quality and Efficiency of Care for Patients with Hip Fractures?
Journal of Aging & Social Policy / Jan 02, 2015
Antonova, E., Boye, M. E., Sen, N., O’Sullivan, A. K., & Burge, R. (2015). Can Bundled Payment Improve Quality and Efficiency of Care for Patients with Hip Fractures? Journal of Aging & Social Policy, 27(1), 1–20. https://doi.org/10.1080/08959420.2015.970844
Seasonal influenza vaccination trends from 2007–2011 in privately insured children and adults in the United States
Vaccine / Nov 01, 2014
Antonova, E., Ambrose, C. S., Kern, D., Block, S. L., Caspard, H., & Tunceli, O. (2014). Seasonal influenza vaccination trends from 2007–2011 in privately insured children and adults in the United States. Vaccine, 32(48), 6563–6568. https://doi.org/10.1016/j.vaccine.2014.07.009
Tibia shaft fractures: costly burden of nonunions
BMC Musculoskeletal Disorders / Jan 26, 2013
Antonova, E., Le, T. K., Burge, R., & Mershon, J. (2013). Tibia shaft fractures: costly burden of nonunions. BMC Musculoskeletal Disorders, 14(1). https://doi.org/10.1186/1471-2474-14-42
Burden of paediatric influenza in Western Europe: a systematic review
BMC Public Health / Nov 12, 2012
Antonova, E. N., Rycroft, C. E., Ambrose, C. S., Heikkinen, T., & Principi, N. (2012). Burden of paediatric influenza in Western Europe: a systematic review. BMC Public Health, 12(1). https://doi.org/10.1186/1471-2458-12-968
Older people presenting to the emergency department after a fall: a population with substantial recurrent healthcare use
Emergency Medicine Journal / Oct 01, 2011
Close, J. C. T., Lord, S. R., Antonova, E. (Jenya), Martin, M., Lensberg, B., Taylor, M., Hallen, J., & Kelly, A. (2011). Older people presenting to the emergency department after a fall: a population with substantial recurrent healthcare use. Emergency Medicine Journal, 29(9), 742–747. https://doi.org/10.1136/emermed-2011-200380
Scope and Severity Index: A Metric for Quantifying Nursing Home Survey Deficiency Number, Scope, and Severity Adjusted for the State-Related Measurement Bias
Journal of the American Medical Directors Association / Feb 01, 2012
Antonova, E., & Zimmerman, D. (2012). Scope and Severity Index: A Metric for Quantifying Nursing Home Survey Deficiency Number, Scope, and Severity Adjusted for the State-Related Measurement Bias. Journal of the American Medical Directors Association, 13(2), 188.e7-188.e12. https://doi.org/10.1016/j.jamda.2011.04.021
Omalizumab substantially improves dermatology‐related quality of life in patients with chronic spontaneous urticaria
Journal of the European Academy of Dermatology and Venereology / Jul 19, 2017
Finlay, A. Y., Kaplan, A. P., Beck, L. A., Antonova, E. N., Balp, M. ‐M., Zazzali, J., Khalil, S., & Maurer, M. (2017). Omalizumab substantially improves dermatology‐related quality of life in patients with chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 31(10), 1715–1721. Portico. https://doi.org/10.1111/jdv.14384
An Updated Review of Food and Drug Administration Warning and Untitled Letters for Clinical Outcome Assessment Claims Between 2013 and 2021
Value in Health / Dec 01, 2023
Sams, L., Slagle, A. F., Symonds, T., Antonova, J., & Globe, D. (2023). An Updated Review of Food and Drug Administration Warning and Untitled Letters for Clinical Outcome Assessment Claims Between 2013 and 2021. Value in Health, 26(12), 1675–1680. https://doi.org/10.1016/j.jval.2023.08.012
The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States
ACR Open Rheumatology / Nov 18, 2021
Dore, R. K., Antonova, J. N., Burudpakdee, C., Chang, L., Gorritz, M., & Genovese, M. C. (2021). The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States. ACR Open Rheumatology, 4(6), 473–482. Portico. https://doi.org/10.1002/acr2.11376
The Impact of Special Focus Facility Nursing Homes on Market Quality
The Gerontologist / Feb 12, 2010
Castle, N. G., Sonon, K., & Antonova, J. (2010). The Impact of Special Focus Facility Nursing Homes on Market Quality. The Gerontologist, 50(4), 519–530. https://doi.org/10.1093/geront/gnq006
Efficacy of niraparib therapy in patients with newly diagnosed advanced ovarian cancer by BRCA and homologous recombination status: PRIMA/ENGOT-OV26/GOG-3012 study
Gynecologic Oncology / Oct 01, 2020
Monk, B. J., & Martin, A. G. (2020). Efficacy of niraparib therapy in patients with newly diagnosed advanced ovarian cancer by BRCA and homologous recombination status: PRIMA/ENGOT-OV26/GOG-3012 study. Gynecologic Oncology, 159, 18. https://doi.org/10.1016/j.ygyno.2020.06.034
Education
University of Wisconsin–Madison
Ph.D., Health system engineering / June, 2008
University of Wisconsin–Madison
M.S., Health Services Research / June, 2006
University of Wisconsin–Madison
M.S., Industrial and system engineering / June, 2005
Ural State University of Economics
B.S., Economics
Experience
Compass Strategy and Research, Inc.
Principal Scientist / February, 2022 — Present
Was hired to maximize treatment value through patient-centered outcomes • Support executive team to enhance product value proposition through robust Value & Access strategy • Champion excellence in HEOR and PRO/COA strategy implementation through effective in-house project management and strategic oversight • Maximize the value propositions of medical products through the development of HEOR and PRO/COA strategy focused on multiple stakeholders (patients, caregivers, regulators, HTA and payer agencies, and policymakers) • Persuasively communicated the unique value of products to multiple stakeholders, securing their support and partnership • Enable excellence and compliance in the planning, execution, and publication of HEOR and PRO/COA research by optimizing scientific planning, oversight, and publication approval processes
Aqtual, Inc.
Head of Value & Access / January, 2023 — December, 2023
Was hired to build V&A capacity and shape the product value proposition • Addressed and resolved pivotal issues to refine business strategies and optimize decision-making in development programs • Crafted and articulated a compelling product value story, tailored to optimize value from the payer perspective • Formulated a robust Value & Access (V&A) strategy, concentrating on current and future indications to enhance market positioning • Established strategic relationships with key payer decision-makers, fostering avenues for impactful collaborations • Facilitated a standout market debut for a company emerging from stealth mode through strategic planning and execution of key publications • Established and maintained company-level standards of excellence and compliance in HEOR and PRO/COA research planning, execution, and publication, through streamlined scientific planning, meticulous oversight, and robust publication approval processes
Gilead Sciences, Inc.
Director, PRO and COA Center of Excellence / March, 2020 — February, 2022
Was hired to ensure excellence in COA strategy, execution, analyses, and publications • Enabled successful PRO discussions with regulatory agencies (FDA, EMA) by contributing to briefing documents and participating in meetings with the FDA • Drove excellence in patient-focused drug development by developing training on the value of PRO/COA for multiple stakeholders and best practices in PRO/COA strategy and research • Ensured success of critical (high-priority and high-visibility) projects by advising therapeutic-area HEOR colleagues on PRO strategy during launches, protocol design, COA analyses, and regulatory communications • Enabled excellence and compliance in the planning, execution, and publication of PRO/COA research by optimizing scientific planning, oversight, and publication approval processes • Maximized the value of Gilead products by optimizing PRO/COA for HTA and payer decisions
Director, Health Economics and Outcomes Research / September, 2017 — February, 2020
Was hired to create a comprehensive research agenda to demonstrate the value of a multi-indication product via real-world evidence and clinical outcome assessment • Led, developed, and executed HEOR strategy supporting a product launch • Communicated the value Gilead products by leading 25+ publications • Gilead Sciences (continued) • Enabled successful publications of PRO and COA in clinical trial result in oncology, inflammation, liver disease • Strengthened clinical programs by informing clinical trial design, statistical analysis plans, and best practices in PRO and COA methodology • Elevated Gilead recognition in the clinical and scientific communities by cultivating and managing relationships with clinical experts and key opinion leaders (KOLs)
Genentech, LLC
Senior Health Economist / February, 2014 — August, 2017
Was hired to lead HEOR activities (economic modeling, real-world evidence, COA research) for 2 sequential launches • Ensured close cross-functional integration of HEOR strategy through collaborative development and execution of HEOR strategic plans • Enabled two successful launches of two line-extensions through RWE, economic modeling, and PRO research • Enabled the successful assessment of PRO in Genentech Phase 4 and observational studies by developing PRO strategy and informing endpoint • Facilitated patient centricity in clinical practice by developing an iOS app (MyHivesDiary) to collect symptoms of chronic idiopathic urticaria (CIU) in daily life • Expanded the value of Xolair by developing publication strategy and leading 50+ peer-reviewed publications (receiving 4 publication awards)
MedImmune, Inc.
Senior Manager, Health Economics and Outcomes Research / March, 2011 — December, 2013
Was hired to support a product launch in the EU, set up and execute a comprehensive research agenda, and communicate the product value through publications • Ensured a successful launch of a MedImmune product by executing and publishing HEOR research (RWE, economic modeling, value dossier) • Advised expansion of value proposition in oncology by outlining the highest unmet need in patients through early-phase economic modeling • Informed national and local policies on pediatric vaccination in the US and UK through economic models demonstrating that vaccination of school-age children protects the elderly from influenza morbidity and mortality
Eli Lilly and Company, Inc.
Research Scientist / July, 2008 — February, 2011
Was hired to support a portfolio of multiple indications to ensure comprehensive value proposition, HEOR strategy • Supported a successful launch of an acquired (short-notice) product through the leadership developing PRO strategy and executing qualitative research to support the PRO instrument design • Ensured breadth and strength of treatment value by leading cross-functional work on the development of value-proposition documents for products in men’s health and musculoskeletal health • Supported the expansion of the treatment value proposition by developing PRO strategy for clinical trials • Maximized the value of treatments by advising clinical trial design and instrument development; represented PRO expertise at the FDA meetings
Links & Social Media
Join Jenya on NotedSource!
Join Now
At NotedSource, we believe that professors, post-docs, scientists and other researchers have deep, untapped knowledge and expertise that can be leveraged to drive innovation within companies. NotedSource is committed to bridging the gap between academia and industry by providing a platform for collaboration with industry and networking with other researchers.
For industry, NotedSource identifies the right academic experts in 24 hours to help organizations build and grow. With a platform of thousands of knowledgeable PhDs, scientists, and industry experts, NotedSource makes connecting and collaborating easy.
For academic researchers such as professors, post-docs, and Ph.D.s, NotedSource provides tools to discover and connect to your colleagues with messaging and news feeds, in addition to the opportunity to be paid for your collaboration with vetted partners.
Expert Institutions
Proudly trusted by
